KA
ALT icon

Kovack Advisors’s Altimmune ALT Stock Holding History

Kovack Advisors’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109K Sell
36,000
-250
-0.7% -$747 0.01% 1040
2026
Q1 		$112K Buy
36,250
+1,035
+3% +$4.39K 0.01% 973
2025
Q4 		$127K Buy
+35,215
New +$154K 0.01% 978

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kovack Advisors's ALT Position: Q2 2026 in Review

Kovack Advisors reduced its Altimmune (ALT) stake by 0.69% in Q2 2026, selling an estimated $747 and leaving 36,000 shares worth $109K. The position accounts for 0.01% of the portfolio, ranked #1040.

Kovack Advisors first reported a position in ALT in Q4 2025 and has held it in 3 quarters since. The position peaked at $127K in Q4 2025. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Kovack Advisors held 36,000 shares of Altimmune worth $109K as of Q2 2026.
  • Kovack Advisors sold 250 Altimmune shares in Q2 2026, an estimated $747.
  • Altimmune made up 0.01% of Kovack Advisors's portfolio in Q2 2026, its #1040 holding.
  • Kovack Advisors first reported a position in Altimmune in Q4 2025 and has held it in 3 quarters since.
  • Kovack Advisors's Altimmune position peaked at $127K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.